Table 4 Results of univariable and multivariable Cox-regression for survival according to dosage reduction
95% CI for HR | |||||
|---|---|---|---|---|---|
p value | Hazard ratio | Lower | Upper | ||
Univariable Cox-regression | |||||
Dosage reduction | No | 1.000 | |||
Yes | .431 | .841 | .547 | 1.294 | |
Multivariable Cox-regression | |||||
Dosage reduction | No | 1.000 | |||
Yes | .600 | .861 | .492 | 1.506 | |
Age | continuous | .118 | .981 | .958 | 1.005 |
Sex | Male | 1.000 | |||
Female | .446 | 1.264 | .692 | 2.310 | |
T stage | T3 | 1.000 | |||
T4 | .229 | 1.541 | .761 | 3.117 | |
TX | .890 | .916 | .265 | 3.170 | |
N stage | N0 | 1.000 | |||
N1 | .981 | .988 | .345 | 2.824 | |
N2 | .713 | 1.225 | .415 | 3.615 | |
NX | .927 | .922 | .161 | 5.266 | |
Grading | G2 | 1.000 | |||
G3 | .302 | 1.354 | .761 | 2.407 | |
GX | .458 | .576 | .134 | 2.474 | |
L stage | L0 | 1.000 | |||
L1 | .726 | 1.215 | .408 | 3.620 | |
LX | .289 | .469 | .116 | 1.901 | |
V stage | V0 | 1.000 | |||
V1 | .872 | .920 | .334 | 2.531 | |
VX | .164 | 2.620 | .675 | 10.165 | |
Charlson Score | 6 | 1.000 | |||
7 | .750 | .892 | .443 | 1.797 | |
8 | .909 | .954 | .426 | 2.138 | |
9 | .609 | 1.605 | .262 | 9.822 | |
Oncological resection/Surgery | No | 1.000 | |||
Yes | .227 | .483 | .149 | 1.570 | |
No of CTX lines | continuous | .797 | 1.053 | .712 | 1.556 |
Biological CTX | No | 1.000 | |||
Yes | .178 | .663 | .364 | 1.207 | |
CTX regimen | FOLFOX- > FOLFIRI | 1.000 | |||
FOLFIRI- > FOLFOX | .691 | 1.177 | .527 | 2.627 | |
FOLFOX | .001 | 3.601 | 1.656 | 7.827 | |
FOLFIRI | .921 | .945 | .309 | 2.892 | |